Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy

Hidemitsu Kitamura,1* Yosuke Ohno,1,2 Yojiro Toyoshima,1,2 Junya Ohtake,1 Shigenori Homma,2 Hideki Kawamura,2 Norihiko Takahashi2 and Akinobu Taketomi2

1Division of Functional Immunology, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University; 2Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Key words: Cancer immunotherapy, dendritic cell, immunosuppression, interleukin-6, STAT 3

Correspondence
Hidemitsu Kitamura, Division of Immunoregulation, Section of Disease Control, Institute for Genetic Medicine, Hokkaido University, Kita-15, Nishi-7, Kita-ku, Sapporo 060-0815, Japan.
Tel: +81-11-706-5520; Fax: +81-11-706-5519;
E-mail: kitamura@igm.hokudai.ac.jp

Funding Information
This work was partially supported by Grants-in-Aid for Scientific Research (C) (25460584 to H. K. and 16K10526 to N. T.) from the Japan Society for the Promotion of Science (JSPS), the Platform Project for Supporting Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (H. K.), the Japan Agency for Medical Research and Development (AMED) (A. T.), and the Joint Research Program of the Institute for Genetic Medicine, Hokkaido University (A. T.).

Received April 3, 2017; Revised July 18, 2017; Accepted July 24, 2017


doi: 10.1111/cas.13332

S

Since the discovery of cancer-related antigens in the 1990s, cancer immunotherapy has developed as a promising cancer treatment based on cancer-specific activation of the host immune system.1,2 To date, many basic studies and clinical trials of cancer peptide vaccines and adoptive T cell therapies have been conducted for the treatment of cancer patients.3,4 However, while some trials have reported clinical efficacy, cancer vaccine therapies are not yet a standard therapy for cancer patients. To develop more effective cancer immunotherapies, it is crucial to induce strong and persistent antitumor immune responses in the tumor microenvironment.

It has been reported that dysfunction of antitumor immunity occurs in tumor-bearing hosts. Various immunosuppressive cytokines, including interleukin (IL)-10 and transforming growth factor (TGF)-β, produced at high levels in tumor-bearing states inhibit the function of antitumor effector T cells. In addition, immune suppressive cells, such as Foxp3+CD4+ regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC), induced from immature myeloid cells in tumor microenvironments are well known to block antitumor immunity.5–7

Recently, effective immune checkpoint therapy using anti-programmed cell death protein-1, anti-programmed death-ligand 1 and/or anti-cytotoxic T lymphocyte (CTL)-associated protein-4 antibodies to activate effector T cells in cancer patients has been reported for various solid tumors.8–10 These results indicate that cancer antigen-specific T cells, which eliminate cancer cells, potentially exist in tumor microenvironments. As a result, blocking negative signals to tumor-infiltrating T cells can restore their cytotoxic function against target cancer cells. Thus, introduction of cancer antigen-specific effector T cells into the tumor microenvironment is required as the first step towards more effective cancer immunotherapy. Dendritic cells (DC), representative antigen-presenting cells, strongly induce antigen-specific immune responses through
activation of CD4+ T and CD8+ T cells. In cancer patients, DC expressing human leukocyte antigen (HLA) class I, HLA class II and co-stimulatory molecules on their cell surface are crucial for induction of cancer-related antigen-specific T helper (Th) cells and CTL through the T cell-DC interaction. Therefore, proper regulation of DC functions in tumor-bearing hosts is important to induce antitumor immunity.

Interleukin (IL)-6, a pleiotropic cytokine with various effects on cells and tissues, is produced by many different cell types, including immune cells, fibroblasts, endothelial cells and tumor cells. IL-6 first binds to the IL-6 receptor (IL-6R). The IL-6/IL-6R complex then associates with the signal-transducing membrane protein gp130, inducing its dimerization to initiate IL-6 signaling. Gp130 dimerization is followed by rapid activation of the Janus kinase (JAK) family and several signaling pathways, including phosphatidylinositol-3-kinase/extracellular signal-regulated kinase/mitogen-activated protein kinase and phosphatidylinositol-3-kinase/extracellular signal-regulated kinase/mitogen-activated protein kinase and signal transducer and activator of transcription 3 (STAT3). STAT3 activation induces numerous effector genes involved in cell proliferation, differentiation and survival.

Previously, it was reported that IL-6 signaling suppresses major histocompatibility complex (MHC) class II expression on murine DC through STAT3 activation, and attenuates CD4+ T cell-mediated immune responses. Furthermore, we found that addition of neutralizing IL-6R enhances T cell responses and inhibits tumor growth in vivo. Next, we confirmed that IL-6 suppresses CD4+ T cell-mediated immunity through downregulation of MHC class II by enhanced arginase activity of DC in tumor-bearing mice. IL-6-mediated STAT3 activation appears to be a critical mechanism for induction of dysfunctional immune system responses in the tumor microenvironment through regulation of antigen-presenting cells. Thus, blockade of IL-6/STAT3 signaling cascades in DC may be a promising approach to overcome the dysfunction of antitumor immunity in cancer patients.

Some studies using murine tumor-bearing models have indicated the positive effects of IL-6 in anti-tumor immunity. A previous paper demonstrated that IL-6 produced by non-hematopoietic stromal cells acted cooperatively with soluble IL-6Rα and thermally induced gp130 to promote E/P-selectin-dependent and ICAM-1-dependent extravasation of cytotoxic T cells in tumors and apoptosis of tumor targets. Another paper revealed that cryo-thermal therapy induced IL-6 at acute phase and shifted the tumor chronic microenvironment from Th2 immunosuppressive and pro-tumorigenic to a Th1 immunostimulatory and tumoricidal state. Because the precise effects of IL-6 on human cancer immunology are unclear compared with those in mice, we have recently focused on the IL-6/STAT3-signaling pathway in human DC. Our aim was to translate the information obtained by murine studies for clinical benefit in human subjects, and to demonstrate the possibility of improving cancer immunotherapy by regulation of the IL-6/STAT3 signaling pathway.

In this review, we first describe IL-6 production in cancer patients and then the regulatory mechanism of MHC/HLA class II expression in murine and human DC in vitro. Then, we discuss the effect of IL-6/STAT3 signaling on the antigen-presenting ability of DC and Th1 immunity in tumor-bearing models. Moreover, we introduce current basic and clinical studies on blocking the effects of the IL-6 signaling cascade on tumor-bearing mouse models and cancer patients. Finally, we propose that proper regulation of the antigen-presenting ability of DC is important for the activation of effector T cells that infiltrate into the tumor microenvironment, and that the IL-6/STAT3 signaling pathway is a promising target to improve cancer immunotherapy.

Interleukin-6 Production in Cancer Patients

Generally, DC immediately activate and initiate T cell immune responses after stimulation by immunological adjuvants such as toll-like receptor (TLR) ligands, whereas in the absence of such maturation signals, most DC remain in an immature form that induces tolerance to self-antigens. Thus, elucidation of the regulating mechanisms of mature and immature statuses is essential for effective vaccine development and prevention of undesirable immune responses by DC in tumor-bearing hosts.

It is well known that patients with advanced cancer are immunocompromised, and cancer progression is closely related to chronic inflammation. IL-6 is a representative pro-inflammatory cytokine. Prospective and retrospective studies have shown that serum IL-6 levels are related to the tumor stage and size, metastasis and survival of colon cancer patients. IL-6/STAT3 signaling pathway suppresses the functions of DC in tumor-bearing hosts.

Interleukin-6 is produced by various cell types, including cancer cells and cancer-associated fibroblasts, as well as toll-like receptor (TLR) ligands. In IL-6-deficient mice, helper T and killer T cell responses were remarkably enhanced in IL-6-deficient mice. These studies suggest that IL-6 is a potent negative regulator of DC maturation and activation. Furthermore, DC-mediated helper T and killer T cell responses were remarkably enhanced in IL-6-deficient mice. These findings suggest that IL-6 is a potent negative regulator of DC maturation in vivo, and that the IL-6/STAT3 signaling cascade in DC may represent a critical target for controlling T cell-mediated immune responses in the tumor-bearing state.

We further demonstrated that the IL-6/STAT3 signaling pathway suppresses MHC class II expression on DC and attenuates CD4+ Th cell responses through activation of lysosomal protease in a mouse model. Inhibitors of lysosomal proteases blocked the reduction of MHC class II αβ-dimer in IL-6-treated DC. In addition, gene overexpression of cathepsin S, a lysosome protease, in DC increased intracellular MHC class II αβ-dimer levels, LPS-mediated surface expression of MHC class II, and suppressed CD4+ T cell activation. These data indicate that IL-6/STAT3-induced excessive activation of lysosomal proteases suppresses the functions of DC through the degradation of MHC class Iαβ-dimer in lysosomes.

Inhibition of Dendritic Cells Maturation by Interleukin-6 through STAT3 Activation

A previous study has demonstrated that IL-6-deficient mice have increased numbers of mature DC, indicating that IL-6 plays a major role in blocking DC maturation in vivo. In this study, STAT3 activation by IL-6 was involved in the suppression of TLR4 ligand and lipopolysaccharide (LPS)-induced DC maturation and activation. Furthermore, DC-mediated helper T and killer T cell responses were remarkably enhanced in IL-6-deficient mice. These findings suggest that IL-6 is a potent negative regulator of DC maturation in vivo, and that the IL-6/STAT3 signaling cascade in DC may represent a critical target for controlling T cell-mediated immune responses in the tumor-bearing state.

We further demonstrated that the IL-6/STAT3 signaling pathway suppresses MHC class II expression on DC and attenuates CD4+ Th cell responses through activation of lysosomal protease in a mouse model. Inhibitors of lysosomal proteases blocked the reduction of MHC class II αβ-dimer in IL-6-treated DC. In addition, gene overexpression of cathepsin S, a lysosome protease, in DC decreased intracellular MHC class II αβ-dimer levels, LPS-mediated surface expression of MHC class II, and suppressed CD4+ T cell activation. These data indicate that IL-6/STAT3-induced excessive activation of lysosomal proteases suppresses the functions of DC through the degradation of MHC class Iαβ-dimer in lysosomes.
activities. Therefore, activation of COX2, as is the case in
immature DC as well as macrophages and MDSC are well
known to show high levels of lysosomal protease and arginase
activities. Therefore, activation of COX2, as is the case in
arginase-1, may be involved in both degradation and transcrip-
tional downregulation of HLA class II levels in DC.

In previous reports, CD14+/HLA-DRlow cells were
increased in the peripheral blood of advanced cancer patients,
and these cells were defined as human MDSC. A recent
study has revealed that IL-11, a member of the IL-6 cytokine
family, is produced in the tumor microenvironment of colorec-
tal cancer patients and induces MDSC in a STAT3-dependent
manner. Taken together, we speculate that STAT3 activa-
tion in peripheral myeloid cells may systemically cause down-
regulation of the surface expression of HLA-DR. In addition
to various immunosuppressive cytokines such as IL-10, IL-11
and TGF-β, IL-6 produced in the tumor microenvironment
may be one of the main cytokines that control the expression
of MHC/HLA class II in a STAT3-dependent manner. There-
fore, IL-6/STAT3 signaling inhibits the maturation of tumor-
infiltrating myeloid cells into antigen-presenting cells and
attenuates subsequent T cell immune responses.

**Suppressive Effects of Interleukin-6 on Dendritic
Cell-mediated Th1 Cell Responses**

The helper functions of antigen-specific Th1 cells, such as pro-
duction of IL-2 and interferon (IFN)-γ, are essential to induce
fully activated CTL in tumor-bearing hosts. A previous
report has demonstrated that a cancer antigen-derived peptide-
containing helper epitope induces CTL efficiently in vitro
according to the helper function of antigen-specific CD4+ T
cells. In fact, a cancer peptide vaccine containing a helper
epitope induced CTL in an advanced cancer patient, and the
patient experienced a clinical benefit. Recent studies have
revealed that IL-6 produced in tumor environments suppresses
the differentiation of IFN-γ-producing Th1 cells and promotes
subsequent tumor formation. These results suggest that activa-
tion of Th1 cells is a crucial event for induction of anti-
cancer immunity in cancer patients.

We demonstrated that the IL-6/STAT3 signaling pathway
impaired the antigen-presenting function of human DC through
downregulation of HLA class II expression, and attenuates
Th1 immunity by decreasing IL-12 production from DC. In
previous reports, CD14+/CD11c− cells were increased in the
donor peripheral blood of advanced cancer patients, and these
cells were defined as human MDSC. Therefore, IL-6/STAT3
signaling pathway may be responsible for the impaired
antigen-presenting function of human DC through down-
regulation of HLA class II expression of DC.

**Recent advances in the study of antigen-specific Th1 cell
function in cancer immunotherapy**

Recent advances in the study of antigen-specific Th1 cell
function in cancer immunotherapy have focused on the role of
biological response modifiers (BRMs) in boosting anti-
cancer immunity. Among the BRMs, IL-12 is a key cytokine
for inducing Th1 immunity because it activates STAT4 in
CD4+ T cells, inducing subsequent IFN-γ secretion. These
results suggest that STAT3 activation in Th1 cells is a crucial
event for induction of anti-cancer immunity in cancer patients.

We demonstrated that the IL-6/STAT3 signaling pathway
impaired the antigen-presenting function of human DC through
downregulation of HLA class II expression, and attenuates
Th1 immunity by decreasing IL-12 production from DC.
CD4+ T cells

**Blockade of the Interleukin-6 Signaling Cascade to
Augment Dendritic Cell-mediated Antitumor Immunity**

Dysfunction of the immune system in the tumor-bearing state
is a critical issue for the development of effective cancer
immunotherapies. A previous study has indicated that IL-6

![Image](image-url)
suppresses antigen-specific CD4+ T cell responses through downregulation of MHC class II on DC in vivo. Based on these findings, we blocked IL-6 signaling by administration of a monoclonal antibody against IL-6 receptor (anti-IL-6R mAb) to enhance antitumor immunity, and confirmed its inhibitory effects on tumor growth. In this study, we found that tumor-infiltrating CD11c+ DC enhanced the arginase-1 mRNA expression level and reduced surface expression of MHC class II in parallel with an increase in serum IL-6 levels at a late stage in tumor-bearing mice. Furthermore, we demonstrated that N(omega)-hydroxy-L-arginine, an arginase-1 inhibitor, blocks the reduction in MHC class II levels on CD11c+ DC during the tumor-bearing state. In vivo injection of the arginase inhibitor at a peritumor site significantly enhanced CD4+ T cell responses and inhibited tumor growth. Therefore, IL-6-mediated arginase activation and the subsequent reduction in MHC class II expression may be involved in dysfunction of the DC-mediated immune system in tumor microenvironments. Accordingly, blockade of the IL-6-arginase cascade may represent a promising approach to overcome the dysfunction of antitumor immunity in tumor-bearing hosts (Fig. 2).

Other Aspects of Interleukin-6 for Anti-tumor Immunity and Tumorigenesis in vivo

Recent studies indicated that the generation of tumor antigen-specific effector T-helper cells was significantly attenuated, and impaired Th1 differentiation was restored by the temporal blockade of IL-6 activity at the T-cell priming phase. The researchers revealed that c-Maf activity was responsible for IL-6/sIL-6R-induced Th1 suppression and defective T-cell-mediated antitumor responses. These data suggest another mechanism for effects of IL-6 that will directly affect T cell function.

Previous papers revealed that IL-6 promotes growth and epithelial–mesenchymal transition of CD133+ cells of non-small cell lung cancer, tumorigenicity of oral cancer stem cells, cell adhesion, cancer stem-like and metastatic spread of prostate tumors, the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells (BCSC), and drug resistance of BCSC. Furthermore, it was reported that CD133+ cells produced IL-6, suggesting that cancer stem cells may potentially reduce anti-tumor immunity in vivo. These findings indicate that IL-6 appears to play a critical role in tumorigenesis of cancer stem cells, suggesting that blockade of IL-6 signaling will be a promising target for the treatment and prevention of recalcitrant tumors.

Future Perspective

Recent clinical trials using a chimeric anti-IL-6 mAb, situximab, have been conducted for patients with metastatic renal carcinoma, prostate cancer, advanced solid tumors and multiple myeloma. These treatments were well tolerated by the cancer patients. Serum C-reactive protein was decreased and anemia caused by chronic inflammation was improved by administration of the anti-IL-6 mAb. These data suggest that blockade of IL-6 signaling might control the status of chronic inflammation in patients with advanced cancers. Recently, a phase I trial combining therapy using an anti-IL-6...
References

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an anti-
10. Brahmer JR, Tykodi SS, Chow LQM et al. Safety and activity of anti-PD-

Disclosure Statement

The authors have no conflicts of interest.

Unsolicited Review Article

Kitamura et al.

Cancer Sci | October 2017 | vol. 108 | no. 10 | 1951


6R mAb, tocilizumab, with carboplatin/doxorubicin and IFN-
α2b has been conducted for patients with recurrent epithelial ovarian cancer. This study reported that immune cells in the IL-6R mAb-treated patients had reduced levels of phospho-
ylated STAT3 and myeloid cells produced more IL-12, while T cells were more activated and secreted higher amounts of effector cytokines including IFN-γ. Patients receiving the highest dose of tocilizumab showed increased levels of serum sol-
uble IL-6R, which was potentially associated with a survival benefit. Based on this evidence, we speculate that IL-6 may be a promising target for cancer immunotherapy through improving the antigen-presenting function of DC and facilitating maturation of antigen-presenting cells into tumor-infiltrating effector T cells against tumor-related antigens including neo-
stem antigens from killed cancer cells (Fig. 3).

It has been reported that the presence of intratumoral T cells, including Th1, Th2 and Th17 cells, Tregs, and CTL, is a good prognostic factor in colorectal cancers. We found that HLA class II expression levels of tumor-infiltrating immune cells are closely related to the invasion of CD4+ T and CD8+ T cells at tumor sites. Therefore, blockade of IL-6/STAT3 signaling to enhance HLA expression on DC combined with other cancer treatments, such as cancer peptide vaccines, immunological adjuvants, immune checkpoint ther-
apies and anticancer drugs, may show more clinical efficacy by restoring the T cell stimulatory ability of antigen-presenting cells in cancer patients.

Previous studies demonstrated that PD-L1 expression levels on cancer cells were augmented by stimulation with IFN-γ, which was generally produced by anti-tumor effector lymphocytes based on type-1 immunity in a STAT-1 dependent manner. PD-L1-expressed cancer cells ordinarily reduce antitumor responses by PD-1-expressing effector cytotoxic T cells. IL-6-deficient condition increased Th1 and Tc1 immunity that may cause augmentation of PD-L1 expression levels on cancer cells and antigen presenting cells, including DC in vivo. Therefore, we speculate that blockade of IL-6/IL-6R signaling will facilitate immune-check point therapy using anti-PD-1/ PD-L1.

TLR ligands such as poly I:C are promising tools to induce antitumor immunity by increasing IL-12 production and maturation of DC in vivo. However, it has been reported that the TLR3/TRIF/MyD88-NF-kb signaling pathway in DC generally induces IL-6 as well as IL-12. Therefore, we speculate that the IL-6-deficient condition promote the antitumor effect of immunoadjuvant therapy using poly I:C.

Based on the present data and previous reports, we speculate that blockade of the IL-6 signaling pathway may promote introduction of antitumor immunity into the tumor-bearing hosts. Such an approach may be a promising strategy for the development of more effective immune checkpoint blockade therapies using anti-PD-1/PD-L1 mAbs and immunological adjuvants such as poly I:C for cancer patients.

The present review proposes that maintenance of the anti-
gen-presenting ability of DC is one of the critical issues for the induction and activation of cancer antigen-specific T cells in the tumor microenvironment. Therefore, a therapeutic strategy to improve the function of DC by inhibition of the IL-6/ STAT3 signaling cascade may be effective in increasing good responses to cancer immunotherapies.
IL-6 as a target in cancer immunotherapy

Unsolicited Review Article

Ohtake J, Ohkuri T, Togashi Y et al. IL-6 as a target in cancer immunotherapy. www.wileyonlinelibrary.com/journal/cas

Tsukamoto H, Senju S, Matsumura K on behalf of Japanese Cancer Association. 28

Yoshitomi M, Yutani S, Matsueda S

Hsich CS, Macatonia SE, Tripp CS

Morinobu A, Gadina M, Strober W

Kortylewski M, Xin H, Kujawski M et al.


